Back

From trials to treatment: real-world vericiguat initiation and residual risk in Germany

29 August 2026 (14:15 - 15:00)
Organised by: Logo
Congress Presentation Part of: Acute heart failure therapies: timing, choices, and comparative effectiveness Pharmacotherapy ESC Professional Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Fabian Kerwagen

University Hospital Wuerzburg, Wuerzburg (Germany)

4 More presentations in this session

Presentation thumbnail
Impact of levosimendan versus dobutamine on 30-day mortality and hospital stay in acute decompensated heart failure: a systematic review and meta-analysis
Doctor H. Amorim Parente (Rio de Janeiro, BR)
Abstract Slides Video
Presentation thumbnail
Early in-hospital initiation of dapagliflozin versus empagliflozin in acute heart failure: impact on in-hospital survival and safety
Doctor N. Benameur (Tangier, MA)
Abstract Slides Video
Presentation thumbnail
Does initiating SGLT2 inhibitors at an early stage of heart failure admission really reduce cardiovascular mortality and first rehospitalization? A meta-analysis of randomized controlled trials
Doctor E. Alupei (RO)
Abstract Slides Video
Presentation thumbnail
Early catheter ablation for atrial fibrillation in acute heart failure: prognostic impact across age and ejection fraction
Doctor A. Okahara (Fukuoka, JP)
Abstract Slides Video

Access the full session

Session thumbnail
Acute heart failure therapies: timing, choices, and comparative effectiveness

The Event

Event poster

ESC Congress 2026

29 August 2026 14:15 CET
You may be interested in
thumbnail
Congress Presentation
Risk of all-cause mortality and heart failure hospitalizations in patients treated with vericiguat in real world settings
17 May 2025
thumbnail
Congress Presentation
Guideline-directed medication therapy use among patients with HFrEF receiving vericiguat: comparing findings from a real-world study to clinical trials
29 August 2025
thumbnail
Congress Presentation
Pre-randomization NT-proBNP trajectory and outcomes in the VICTOR trial
30 August 2026
thumbnail
Congress Presentation
Primary care management of chronic heart failure in Germany: prevalence, diagnostics, and guideline-directed therapy in WATCH-HF 1.0 vs 2.0
30 August 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources